Replies to post #465269 on NorthWest Biotherapeutics Inc (NWBO)

[extrooper]

Short would throw their mother into a volcano if they thought they could get paid. I will have to believe TLD and approval is near.

[antihama]

Nice Summary Dendream. It's a keeper, however, I'm going to tweak 2020 in red as follows for my own head.

Shorty decries… same old same old, when will you people learn that they are never releasing results?

What does momentum look like?

2015 study halts new screening of patients but continues enrollment and treatment and trial. Shorty stops at study halted (erroneous). Stock price pummeled.

2017 PFS trigger hit but study continues. 2017 Blinded, grouped data submitted for publication showing substantial increase in OS vs historical controls AND patients in screening all placed on treatment, no more placebo option. New patents. Shorty says they are hiding data. Stock price dropped after rally.

2018 OS trigger finally hit almost a year and a half after 2017 prediction, updated unblinded data presented showing improved long term survival vs 2017 data. New patents. Shorty says they did interim and study failed (erroneous), when will you learn. Company again declares no interim efficacy performed. Working towards data lock.

2019 company revises SAP and study endpoints to compare treated patients to contemporaneous pivotal trial controls and declares seeking approval for one and only one SAP to four regulators (US, EMA, UK, and Canada). Company changes Combo Checkpoint trial to Keytruda. Shorty says LP a criminal fleecing investors, doing it again with Advent. Stock price hits all time low.

2020 Uplist consultants added, Canada filing consultant hired full time, Flaskworks with automated manufacturing devices acquired. Database locked. PR says six step process ending in publication. LL presents Combination trial with Poly ICL shows improved efficacy. LL starts new Combo Checkpoint trial. EMA and UK post new SAP trial endpoints with contemporaneous control comparisons (The Board found out ~Oct 8). SNO 2020 has added the “Late-Breaking” abstract title back to Dr. Linda Liau live DCVax oral presentation (LTBK-02) on the P3 trial. Her presentation is scheduled for 11/20/2020 in Plenary 1 (The Board found out in early Sept) Stock price rallies to $2.50. Shorty says fraud, never releasing data. The Board finds out early Nov the abstract is withdrawn. EDIT: Thinking back on it, I was being gung ho about the abstract in mid Oct and Flipper corrected me back then that the abstract was withdrawn which is something I missed during a mid Oct vacation. Stock price falls.

2021 LP says six step process ending in publication. Company enters ‘Quiet Period’ LL presents all kinds of updated data including exciting prelim results with CI combo. Stock prices rallies to $2.15. Shorty say fraud, when will you learn. Stock price falls. Patents, patents, more patents. Company starts Premarket Promotion Campaign. UK manufacturing facility completed. UK manufacturing facility approved for production. Stock price flops.

2022 Manufacturing begins. UK treatment sites for specials expands throughout UK. UK continues treating GBM patients AND other cancers with DCVax in Specials Program. FDA publishes position statement in support of external control arm use in pivotal trials. LL provides more updates including new data triple Combo Trial and confirms new SAP accepted by FDA. More new Patents for Flaskworks and Combination with Checkpoint Inhibitors. Stock price rallies. Shorty says when will you learn, never releasing data. Stock rally continues. LL starts new speaking tour.

And we wait… Company purchases Exhibit Booth and Promotional Product Theater at ASCO. May is GBM awareness month. Longs say breakthrough data and global approvals coming soon

Shorty says when will you learn, they will never provide TLD.

Who do you believe?